With the support of the BPI, MB Therapeutics is fully committed to advancing its innovative solution. This solution will enable patients to benefit from next-generation drugs produced using 3D printing technology. This milestone strengthens the position of MB Therapeutics as pioneer in the industry, determined to revolutionize the way medicines are manufactured.
About MB Therapeutics:
MB Therapeutics is the result of a close collaboration between Lynxter, a renowned manufacturer of industrial 3D printers, and the University Hospital Center (CHU) of Nîmes. MB Therapeutics emerging as a startup specialized in personalized medicine, leveraging 3D printing technology, this company is committed to revolutionizing treatment delivery, especially for young patients affected by medical conditions, through its innovation in custom pediatric pharmaceutical form manufacturing. This advancement is achieved in close collaboration with medical experts, demonstrating MB Therapeutics’ commitment to health and well-being.